▟ Vinebot intrinsic value, daily

← back

MRSH Marsh McLennan

insurance · valued with opus medium conviction · deep-dived 2026-10-22

STRONG SELL
Intrinsic value$65.86
Price (at call)$190.56
Margin of safety -65.4%
vs market (rating basis) -49.3%

Elite fee franchise with steady 26% ROE, but the market already pays a full price for it.

The story

Marsh McLennan is the largest global insurance broker and consultant, an asset-light fee franchise that earns commissions rather than taking underwriting risk, so its returns are structurally high and far less cyclical than a carrier's. The trailing 26% ROE sits below the roughly 28-30% of 2022-2023, pulled down by the debt-funded McGriff acquisition, added goodwill and integration costs. Book equity is small next to earnings power because of decades of buybacks and acquired intangibles. The cycle risk is a softening P&C pricing market and slower organic growth (now mid-single digits after 7-9%), not credit losses.

A 26% normalized ROE fits a broker with a long, stable record of 25-30% returns and assumes no rebound to the prior peak, while mean reversion is modest because it holds no underwriting balance sheet. Book grows only about 7% because roughly 75-80% of earnings go out as dividends and buybacks, and terminal growth of 4.5% stays below the 5.15% risk-free rate. A beta of 0.85 (cost of equity about 9.0%) sits just under the 0.9 anchor, reflecting recurring fee revenue; because RI anchors on a buyback-shrunk book, it will undervalue this franchise versus the market, which prices earnings power rather than equity.

Value drivers

Return on equity (normalized)25.0%
Book-value growth (Y1)7.0%
Terminal book growth4.5%
Beta0.85
Failure probability1.0%
Cost of equity9.0%

Valuation bridge

PV of excess returns11.64B
PV of terminal excess5.00B
Equity value31.43B
÷ shares → per share$65.86

Projected excess returns on equity

YrBook equityROEExcess returnPV
115.10B 25.0%2.42B 2.22B
216.16B 23.4%2.34B 1.97B
317.24B 21.9%2.23B 1.72B
418.35B 20.3%2.08B 1.48B
519.49B 18.8%1.91B 1.24B
620.63B 17.2%1.70B 1.01B
721.79B 15.6%1.45B 797.35M
822.95B 14.1%1.17B 590.78M
924.11B 12.5%858.17M 396.07M
1025.27B 11.0%505.33M 214.02M

Key risks

  • Softening commercial P&C rates and lower fiduciary interest income compress organic growth and margins
  • McGriff integration and acquired goodwill dilute ROE and raise leverage
  • Oliver Wyman and Mercer consulting are cyclical, and AI-driven disintermediation could erode broker commissions over time

Catalysts

  • McGriff cost synergies and middle-market cross-selling lift margins toward 26%+
  • Continued buybacks and deleveraging restore ROE toward the 28-30% range

History

DatePriceIntrinsicMoSRating
2026-10-22$190.56 $65.86 -65.4% STRONG SELL
2026-09-21$175.01 $56.41 -67.8% SELL
2026-08-19$186.37 $58.04 -68.9% STRONG SELL
2026-07-16$176.22 $60.68 -65.6% STRONG SELL
2026-06-23$163.84 $61.07 -62.7% STRONG SELL